Statin-related adverse events: A meta-analysis

      This paper is only available as a PDF. To read, Please Download here.



      The absolute frequencies of adverseevents (AEs) between statins and placebo are very low in clinical trials, making clinical interpretation and application difficult.


      This meta-analysis was intended to synthesize the collective AE data observed in prospective randomized clinical trials to facilitate clinical interpretation.


      Using the search terms atorvastatin, simvastatin,pravastatin, rosuvastatin, fluvastatin, lovastatin, prospective trial, and randomized trial, the MEDLINE/EMBASE and the Cochrane Collaboration databases were reviewed for prospective randomized primary and secondary prevention trials of statin monotherapy. Nonrandomized uncontrolled studies and those missing AE data were excluded. The Mantel-Haenszel test for fixed and random effects was used to calculate odds ratios (ORs) and log ORs.


      Eighteen trials including 71,108 persons, and 301,374 person-years of follow-up were represented in this analysis. There were 36,062 persons receiving a statin and 35,046 receiving a placebo. Statin therapy increased the risk of any AE by 39% (OR = 1.4; 95% CI, 1.09–1.80; P = 0.008; NNH [number needed to harm] = 197) compared with placebo. Statins were associated with a 26% reduction in the risk of a clinical cardiovascular event (OR = 0.74; 95% CI, 0.69–0.80; P < 0.001; number needed to treat = 27). Treating 1000 patients with a statin would prevent 37 cardiovascular events, and 5 AEs would be observed. Serious events (creatine phosphokinase >10 times the upper limit of normal or rhabdomyolysis) are infrequent (NNH = 3400) and rhabdomyolysis, although serious, is rare (NNH = 7428). Atorvastatin was associated with the greatest risk of AEs and fluvastatin with the least risk. Simvastatin, pravastatin, and lovastatin had similar odds of AEs. Nonurgent AEs such as myalgia and liver function elevations were responsible for approximately two thirds of AEs reported in trials.


      Statin therapy was associated withgreater odds of AEs compared with placebo but with substantial clinical benefit. Similar rates of serious AEs were observed between statin and placebo.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • National Heart, Lung, and Blood Institute
        • American College of Cardiology Foundation, and the American Heart Association
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
        • Thompson P.D.
        • Clarkson P.
        • Karas R.H.
        Statin-associated myopathy.
        JAMA. 2003; 289: 1681-1690
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
        • et al.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • CARDS Investigators
        • et al.
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):Multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • Davidson M.
        • Ma P.
        • Stein E.A.
        • et al.
        Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
        Am J Cardiol. 2002; 89: 268-275
        • Ballantyne C.M.
        • Houri J.
        • Notarbartolo A.
        • et al.
        • Ezetimibe Study Group
        Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blindtrial.
        Circulation. 2003; 107: 2409-2415
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • Treating to New Targets (TNT) Investigators
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Serruys P.W.
        • Foley D.P.
        • Jackson G.
        • et al.
        A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results ofthe fluvastatin angiographic restenosis (FLARE) trial.
        Eur Heart J. 1999; 20: 58-69
        • Serruys P.W.
        • de Feyter P.
        • Macaya C.
        • Lescol Intervention Prevention Study (LIPS) Investigators
        • et al.
        Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial.
        JAMA. 2002; 287: 3215-3222
        • Riegger G.
        • Abletshauser C.
        • Ludwig M.
        • et al.
        The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment.
        Atherosclerosis. 1999; 144: 263-270
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Cholesterol and Recurrent Events Trial Investigators
        • et al.
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterollevels.
        N Engl J Med. 1998; 339: 1349-1357
        • Jukema J.W.
        • Bruschke A.V.
        • van Boven A.J.
        • Regression Growth Evaluation Statin Study (REGRESS)
        • et al.
        Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels.
        Circulation. 1995; 91: 2528-2540
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • et al.
        • West of Scotland Coronary Prevention Study Group
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1308
        • Pitt B.
        • Mancini G.B.
        • Ellis S.G.
        • et al.
        Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC Iinvestigation.
        J Am Coll Cardiol. 1995; 26: 1133-1139
        • de Lemos J.A.
        • Blazing M.A.
        • Wiviott S.D.
        • A to Z Investigators
        • et al.
        Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial.
        JAMA. 2004; 292: 1307-1316
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Olsson A.G.
        • Pears J.
        • McKellar J.
        • et al.
        Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
        Am J Cardiol. 2001; 88: 504-508
        • Downs J.R.
        • Clearfield M.
        • Weis S.
        • Air Force/Texas Coronary Atherosclerosis Prevention Study
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS.
        JAMA. 1998; 279: 1615-1622
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • et al.
        • Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group
        Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial.
        Lancet. 2002; 360: 1623-1630
        • Sweeting M.J.
        • Sutton A.J.
        • Lambert P.C.
        What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
        Stat Med. 2004; 23: 1351-1375
        • Sever P.S.
        • Dahlof B.
        • Poulter N.R.
        • ASCOT Investigators
        • et al.
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lip Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial.
        Lancet. 2003; 361: 1149-1158
        • de Denus S.
        • Spinler S.A.
        • Miller K.
        • Peterson A.M.
        Statins and liver toxicity: A meta-analysis.
        Pharmacotherapy. 2004; 24: 584-591